Topiramate (Epilepsy)

Neural Tube Defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7662
R22680		 Tomson (Topiramate), 2018 Neural tube defects at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 5.53 [0.22;136.28] C 0/152   1/2,514 1 152
ref
S9837
R37711		 Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 Neural Tube Malformations at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 7.23 [0.14;369.08] C
excluded (control group) 		0/44   0/315 0 44
ref
S9838
R37715		 Vajda (Topiramate) (Controls unexposed, sick), 2013 Neural Tube Malformations at least 1st trimester prospective cohort unexposed, sick Adjustment: No 3.37 [0.07;172.23] C 0/44   0/147 0 44
ref
S6061
R15758		 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Neural tube defect 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 7.82 [0.31;196.48] C 0/28   1/647 1 28
ref
Total 3 studies 5.56 [0.78;39.78] 2 224
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Topiramate), 2018Tomson, 2018 1 5.53[0.22; 136.28]115238%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Vajda (Topiramate) (Controls unexposed, sick), 2013Vajda, 2013 2 3.37[0.07; 172.23]04425%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 3 7.82[0.31; 196.48]12837%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 5.56[0.78; 39.78]22240.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate; 2: Topiramate) (Controls unexposed, sick; 3: Topiramate) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.56[0.78; 39.78]22240%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.37[0.07; 172.23]-44 -NAVajda (Topiramate) (Controls unexposed, sick), 2013 1 exposed to other treatment, sickexposed to other treatment, sick 6.57[0.68; 63.77]21800%NATomson (Topiramate), 2018 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 2 Tags Adjustment   - No  - No 5.56[0.78; 39.78]22240%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 3 All studiesAll studies 5.56[0.78; 39.78]22240%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 30.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9837

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.37[0.07; 172.23]-44 -NAVajda (Topiramate) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 6.73[0.94; 48.15]22240%NATomson (Topiramate), 2018 Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 30.510.01.0